Novartis Sees The Light And Plumps For Alcon Spin-Off
Having acquired Alcon for an eye-watering $52bn seven years ago, the Swiss major has decided that spinning off the eyecare business which has finally returned to growth (but is worth about half what Novartis paid in 2011) makes the most sense as it becomes a company even more focused on pharma.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
The Swiss major has made a larger-than-expected bolt-on buy, using a large chunk of its $13bn windfall from GSK to get hold of a potential cure for spinal muscular atrophy and an additional gene therapy platform, as well as manufacturing capabilities.
The Swiss giant's Sandoz division is exploring options for its underperforming US oral generics unit but reports that it may be considering a sale of the latter go against Novartis' previous comments and observers are struggling to see the rationale behind such a move.